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Abstract
CEACAM1, CEA/CEACAM5, and CEACAM6 are cell adhesion molecules (CAMs) of the carcinoembryonic antigen (CEA) family
that have been shown to be deregulated in lung cancer and in up to 50% of all human cancers. However, little is known
about the functional impact of these molecules on undifferentiated cell growth and tumor progression. Here we
demonstrate that cell surface expression of CEACAM1 on confluent A549 human lung adenocarcinoma cells plays a critical
role in differentiated, contact-inhibited cell growth. Interestingly, CEACAM1-L, but not CEACAM1-S, negatively regulates
proliferation via its ITIM domain, while in proliferating cells no CEACAM expression is detectable. Furthermore, we show for
the first time that CEACAM6 acts as an inducer of cellular proliferation in A549 cells, likely by interfering with the contact-
inhibiting signal triggered by CEACAM1-4L, leading to undifferentiated anchorage-independent cell growth. We also found
that A549 cells expressed significant amounts of non-membrane anchored variants of CEACAM5 and CEACAM6,
representing a putative source for the increased CEACAM5/6 serum levels frequently found in lung cancer patients. Taken
together, our data suggest that post-confluent contact inhibition is established and maintained by CEACAM1-4L, but
disturbances of CEACAM1 signalling by CEACAM1-4S and other CEACAMs lead to undifferentiated cell growth and
malignant transformation.
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Introduction
Lung cancer is the most common cause of cancer and cancer
related mortality worldwide[1]. Tumor-progression is character-
ized by the invasion of tumor cells into the surrounding tissue.
Their ability to form metastases in distant organs is a poor
prognostic factor indicating disease dissemination[2]. The vast
majority of primary lung tumors are carcinomas, derived from
epithelial cells. Although their genetic and phenotypic properties
are still not well defined[3–5], various cell adhesion molecules
(CAMs) appear to play a critical role in the processes of invasion
and metastasis[6,7]. Normally CAMs tightly orchestrate tissue
structure by their ability to mediate cell-cell interaction and
contact inhibition. Contact inhibition describes the process of
arresting proliferation when cells come into contact with each
other. Thus, the cells remain in a confluent layer with no piling up
or dissociation of cells from the monolayer. In the case of
malignant transformation, alterations of CAM expression and
function occur. Members of the carcinoembryonic antigen (CEA)
related cell adhesion molecule (CEACAM) family are known to be
deregulated in various tumors, and represent one example of such
proteins. CEACAMs are expressed in normal epithelia, angio-
genically activated endothelia, and haematopoetic cells, and
mediate homotypic and heterotypic cell-cell interactions[8–10].
The functions mediated by CEACAMs differ widely depending on
the growth stage and activation status of the cell. A number of
CEACAM family members have been found to be involved in the
processes of cancerous growth and invasion defining them as
either tumor suppressors or as poor prognostic markers for the
progression of malignancies[10–13]. CEACAMs belong to the
immunoglobulin (Ig) superfamily and thus appear as highly
glycosylated proteins with the typical N-terminal variable Ig-like
domain followed by 0 to 6 constant Ig-like domains, and either a
hydrophobic transmembrane domain with a cytoplasmic tail
(CEACAM1-CEACAM4), or a glycosylphosphatidylinositol (GPI)
lipid moiety (CEACAM5-CEACAM8)[14–16]. In epithelia, four
distinct CEACAMs have been demonstrated, namely CEACAM1,
CEACAM5, CEACAM6 and CEACAM7[15]. Furthermore,
CEACAM1 occurs in four major splice variants with either three
or four Ig domains and either a short (S) or a long (L) cytoplasmic
domain consisting of 12 aa or 73 aa residues, respectively, giving
the following variants: CEACAM1-3S, CEACAM1-4S, CEA-
CAM1-3L and CEACAM1-4L[15,17]. The cytoplasmic domain
of CEACAM1-3/4L possesses an immunoreceptor tyrosine-based
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can recruit and activate SH2 domain-containing tyrosine kinases
and tyrosine phosphatases[18,19]. The interactions of CEA-
CAM1-L with these enzymes play an important role for regulating
signaling cascades and cellar functions [18,20]. Although CEA-
CAM1-S lacks tyrosine residues in its cytoplasmic domain, it also
mediates cell-cell interactions[9,21].
Different members of the CEACAM family or the different
isoforms of CEACAM1 can have different activities[8,14].
However, little is known about the differential expression patterns
of CEACAMs and their role for cell-cell interactions in pulmonary
epithelial cells. Interestingly, Laack et al. identified CEACAM1
expression as a novel prognostic marker in adenocarcinomas of the
lung. In this study patients with adenocarcinomas expressing
CEACAM1 had a significantly worse overall and disease-free
survival in comparison with those who had a CEACAM1-negative
tumor[22]. In addition, Sienel et al. reported that elevated
CEACAM-1 expression in primary non small cell lung cancer
(NSCLC) correlates with lung cancer progression[13]. The human
lung adenocarcinoma cell line A549 represents a well established
model for pulmonary epithelial cells[20,23–25]. Although these
cells are known to expresses CEACAM1[20,26,27], the exact
expression pattern and function of CEACAMs in this cell line are
not yet defined. Like other carcinoma cell lines, A549 cells are a
non-homogenous cell population with several subpopulations,
each with various characteristics[3,28,29]. Interestingly, Croce et
al. reported specific findings about morphological and functional
heterogeneity in four different A549 subpopulations[3]. They
demonstrated that three A549 subpopulations, which represented
the non-tumorigenic (NT) A549 cells with retained characteristics
of more differentiated adenocarcinomas, formed well spread
monolayers, exhibited decent contact inhibition, and were not
tumorigenic in a nude mice system. In contrast, cells of a fourth,
more undifferentiated subpopulation, also demonstrated normal
cobblestone-like epithelial growth during proliferation to a
confluent monolayer, however, some cells overcame contact
inhibition and exhibited anchorage independent growth on top
of the A549 monolayer. Importantly, cells of this population were
demonstrated to be tumorigenic in nude mice and thus were
named tumorigenic (T) A549 cells[3].
These observations prompted us to investigate the relationships
of the expression pattern and function of different CEACAMs with
proliferation and contact mediated growth inhibition in A549 cells.
In addition, the role of the CEACAM1-L and -S splice variants
and the cytoplasmic ITIM domain in cellular morphology and
growth behavior were studied. Our results suggest that the
expression pattern and the interplay of CEACAM1 with different
CEACAMs are of central importance for the regulation of
proliferation and contact inhibition. Thus, CEACAM mediated
functions appear to be important regulators of the invasive and
metastatic behavior of tumor cells.
Results
The Non-Tumorigenic A549-NT and the Tumorigenic
A549-T Subpopulations Differed in Contact-Mediated
Growth Inhibition Properties
First we isolated distinct A549 subpopulations by density
gradient centrifugation as described by Croce et al.[3] and
characterized their CEACAM expression pattern. Density gradi-
ent centrifugation of A549 cells resulted in four different
subpopulations: subpopulation A at the top of the gradient in
fraction 0–3 corresponding to the density of 1.035, subpopulation
B in the fraction 4–6 (density 1.040), subpopulation C in fraction
7–9 (density 1.050) and subpopulation D in fraction 10–12 (density
1.060). Cells accumulate at higher density fractions due to their
size and granularity, which usually reflects an activated cell status.
In accordance with published results, we could subdivide A549
cells in two groups as evidenced by their morphology and growth
behavior. One corresponded to the non-tumorigenic like subpop-
ulations A549-A, -B and -C, and the other to the tumorigenic
A549-D[3]. To simplify our further studies we combined the
subpopulations A549-A, -B and -C and named them A549-NT
(non-tumorigenic) and A549-T (tumorigenic), respectively.
Phase-contrast microscopy revealed that under standard culture
conditions sub-confluent A549-NT and -T occurred as scattered
colonies of associated cells (Figure 1A). However, confluent A549-
NT cells appeared as cobblestone monolayer, characteristic of
epithelial cell growth, consistent of closely associated cells with a
typical polygonal, epithelial-like morphology indicating a stringent
contact inhibition of cell growth (Figure 1B). In addition, this
subpopulation formed tight cell-cell contacts leading to a
significant prolongation of the trypsin treatment necessary for
harvesting if compared with the time needed to harvest
exponential growing A549-NT cells. The A549-T subpopulation
also grew as a normal epithelial monolayer. However, in contrast
to the A549-NT, some cells piled up on each other showing
anchorage independence. These cell aggregates were found mainly
at the top of the monolayer together with suspended cells
(Figure 1C). Over time, the spheroid aggregates detached, floated
unbound on top of the monolayer and formed proliferating
colonies containing approximately 4–400 cells. After seeding
A549-T spheroids into new culture vessels, most of the cells
attached within a few hours (Figure 1D), grew to a confluent
monolayer and again generated detached spheroids of growing
Figure 1. Representative images of different A549 cell clones
demonstrating their morphological heterogeneity by phase
contrast imaging. Subpopulation A549-NT grown exponentially (a),
to tight confluence forming cell-contact inhibited monolayers (b). Tight
confluent subpopulation of A549-T (c) piled up on the monolayer
revealing the ability to survive and proliferate independently of cell-
matrix anchorage, leading to detached spheroidal colonies on top of
the monolayer. (d) Spheroidal A549-T colonies seeded into fresh culture
vessels attached and grew as monolayers. Bar, 50 mm.
doi:10.1371/journal.pone.0008747.g001
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approximately 24 hours and A549-T cells of approximately
20 hours as determined by cell cycle determinations (data not
shown).
The A549-NT and A549-T Subpopulations Revealed
Different CEACAM Expression Patterns
These observations concerning different growth properties of
the A549 subpopulations led us to assume that different expression
patterns of CEACAMs might be important in the loss of contact
inhibition in these cells. Subsequently, the cell surface expression
of CEACAM1, CEACAM5, CEACAM6, and CEACAM7 was
measured on trypsin-dissociated A549-NT and A549-T cells
harvested from non-confluent, confluent monolayers, or - in the
case of A549-T cells, – cells growing as spheroids, by flow
cytometry. As shown in Figure 2, neither proliferating cells of
subpopulations cultivated in the log phase, nor A549-T cells
growing as spheroids, expressed CEACAM1, CEACAM5, CEA-
CAM6, or CEACAM7 on their cell surface. In contrast, in the
tightly confluent monolayer of both the A549-T and A549-NT cell
subpopulations, we found significant cell surface expression of
CEACAM1, but not CEACAM5, in all A549 cells (Figure 2A).
However, while cells of the A549-NT subpopulation also did not
express cell surface bound CEACAM6, around 15% of the A549-
T cells expressed significant levels of CEACAM6 on their cell
surface (15%66%, n=7; Figure 2, lower panel). Western blot
analyses confirmed that non-confluent A549 cells did not express
CEACAM1, CEACAM5, or CEACAM6 (Figure 2B). Confluent
A549 cells showed significant levels of CEACAM1, but in addition
revealed a significant expression of CEACAM5 and CEACAM6
as well (Figure 2B). Thus, CEACAM5 and CEACAM6 proteins
were expressed in confluent A549 cells, but apparently they did
not appear at the cell surface except for some CEACAM6 in a
minor fraction of cells (Figure 2A). To elucidate the discrepancy in
our findings, we analyzed the cell culture supernatant of confluent
A549 cells. We found that both CEACAM5, CEACAM6, and, to
a minor extent, CEACAM1, were released into the cell culture
supernatant of confluent A549-NT (Figure 2C) and A549-T cells
(data not shown).
CEACAM1 Is Mainly Expressed in the Post-Confluent
Growth Phase of A549 Cells
To analyze the regulation of the distinct expression patterns of
CEACAMs found in altered growth stages in more detail, tightly
confluent un-separated A549 cells were seeded into culture vessels
with low cell density. Then cells were constantly cultured in
exponential growth phase for one, two and three days,
respectively. Initially, absolute CEACAM1 expression on the
surface of confluent A549 cells was analyzed by quantitative flow
cytometry. As shown in Figure 3A an approximate expression of
17,00063020 (n=4) molecules per cell was observed. One day
later (day 1) the CEACAM1 expression dropped to 660061523
(n=4) molecules per cell, and continued to decrease until no
CEACAM1 expression on the cell surface was detectable on day 3
(Figure 3A). Further flow cytometric analyses of cells that were
kept non-confluent for up to 10 days, revealed that CEACAM1
did not appear on the cell surface (data not shown). This finding
was confirmed by Western blotting, while some minor CEACAM1
expression in lysates of exponential proliferating A549 cells
harvested on day 3 was still detectable (Figure 3B). In addition
to the significant decrease of CEACAM1 expression, a clear
reduction of CEACAM5 and CEACAM6 protein from day zero
to day three was found (Figure 3B). Thus, cell-cell contact seemed
to play an important role in regulating the expression of
CEACAMs in both A549 subpopulations.
Next, we investigated the kinetics of CEACAM1 expression
from just confluent A549 cells to up to seven days post-confluence.
As shown in Figure 3C, we found that A549 cells that had just
reached confluence did not express CEACAM1. However, as soon
as A549 cells entered the post-confluent growth arrest state, an
increasing fraction of cells started to express high amounts of
CEACAM1. At day seven expression of CEACAM1 could be
detected on every cell of the A549 monolayer (Figure 3C).
According to these results, not only the initial cell-cell contact, but
also entering the growth arrest state, precedes the cell surface
expression of CEACAM1. Thus CEACAM1 does not cause, but
rather stabilizes and maintains contact inhibition. The expression
of CEACAM5 and CEACAM6 in the A549 cells also varied with
cell confluence in a similar manner (data not shown).
A549-NT and A549-T Cells Expressed CEACAM1 Isoforms
at a Similar Ratio of Total L Compared to Total S Isoforms
In principle four different CEACAM1 splice variants are known
to exist in human epithelia, namely CEACAM1-3S, CEACAM1-
4S, CEACAM1-3L and CEACAM1-4L. To analyze these splice
variants in tightly confluent A549-NT and A549-T cells, we
established four different quantitative RT-PCRs, which discrim-
inated between these splice variants. We found that post-confluent
contact inhibited A549 cells of both subpopulations expressed all
four of these CEACAM1 isoforms (Figure 4 and Table 1).
CEACAM1-4L appeared to be the predominant isoform ex-
pressed followed by CEACAM1-3S (Table 1). CEACAM1-4S and
CEACAM1-3L were expressed at much lower levels. In general,
the sum of the expression of the two L isoforms (gL) was greater
than the sum of the two S isoforms (/gS), and there was no
significant difference between the two subpopulations A549-NT
and A549-T with respect to the gL/gS ratio.
CEACAM1-4L Induces Contact-Mediated Inhibition of Cell
Growth in A549 Cells.
To analyze the functional impact of the different CEACAMs,
we altered their expression patterns by stable transfection of
parental A549 cells with CEACAM1-4L, CEACAM1-4S, the
ITIM-mutant form of CEACAM1 [CEACAM1-4L(Y459F/
Y486F)], CEACAM5 and CEACAM6, respectively. Since prolif-
erating A549 cells did not express CEACAMs, the transfection
success could be monitored by flow cytometry utilizing exponen-
tially growing A549 transfectants. Empty vector transfected A549
cells served as a control and showed no expression of CEACAMs
in the proliferative stage (Figure 5A, a). In contrast, A549-
CEACAM1-4L (Figure 5A, b), A549-CEACAM1-4L(Y459F/
Y486F) (Figure 5A, c) and A549-CEACAM5 (Figure 5A, d) cell
lines revealed a strong exogenous CEACAM expression, respec-
tively. The capability to produce A549-CEACAM5 cell lines
demonstrated that in principle A549 cells are able to express GPI-
anchored CEACAMs on their cell surface. Unexpectedly, we were
not able to establish stable transfectants of A549-CEACAM1-4S
and A549-CEACAM6, although the individual vectors transfected
into HeLa cells resulted in CEACAM1-4S and CEACAM6
expression, respectively, proving the efficacy of these vectors (data
not shown). Repeated transfections of A549 cells with CEACAM1-
4S and CEACAM6 were carried out resulting in A549 cells, which
were no longer able to exhibit normal proliferation. Analyzes by
phase-contrast microscopy revealed that A549-CEACAM1-4S
and A549-CEACAM6 cells, which initially survived the G418-
selection procedure, detached from the culture vessel and
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CEACAM6, several A549-CEACAM1-4S cells remained attached
on the cell culture vessel and partially formed giant cells containing
several nuclei (Figure 5B, e). This finding implied a malfunction of
the regular cell division processes caused by over-expression of
CEACAM1-4S. Compared with un-transfected and control-vector
transfected A549 cells, A549-CEACAM1-4L exhibited a marked
increase of the homogeneous, cobblestone-like epithelial cell
Figure 2. Characterization of the cell surface expression of different CEACAMs in A549-NT and A549-T cells. A) A549 subpopulations
collected from different cell growth stages (as indicated) were stained for CEACAM1 with mAb clone 283340, for CEACAM5 with Col-1, for CEACAM6
with mAb 9A6 and for CEACAM7 with BAC2 (thick line). The background fluorescence was determined by incubating the cells with control IgG
antibody instead of primary anti-CEACAM antibody (thin line). Subsequently, samples were analyzed by flow cytometry revealing CEACAM1
expression in confluent A549-NT and A549-T cells. Additionally, a minor fraction of confluent A549-T cells expressed CEACAM6. The data shown are
representative of three independent experiments. B) Determination of different CEACAMs in whole cell lysates of A549 cells cultured in the non-
confluent log phase, the confluent phase and the spheroidal unanchored growing cells by immunoblotting with mAb specific for CEACAM1,
CEACAM5 and CEACAM6. The detection of beta-actin served as a loading control. The data shown are representative of three different experiments.
C) Soluble CEACAM1, CEACAM5 and CEACAM6 forms are released in the cell culture supernatant of confluent A549 cells. The released CEACAM1,
CEACAM5 and CEACAM6 molecules were quantified by specific sandwich ELISA as described in the Materials and Methods section. The mean values
6 SD (*p#0.005) were determined from triplicates. The experiment was repeated twice.
doi:10.1371/journal.pone.0008747.g002
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of contact inhibition (Figure 5B, b). Importantly, none of the
CEACAM1-4L over-expressing cell lines piled up from the
confluent monolayer, and no spheroidal cell aggregates were
formed. To determine, whether an intact cytoplasmic tail of
CEACAM1-4L is essential for mediating the improved contact
inhibition found in A549-CEACAM1-4L, un-separated A549 cells
were stably transfected with an expression plasmid coding for a
cytoplasmic ITIM mutant form of CEACAM1-4L[3,30]. We
found, that unlike CEACAM1-4L over-expressing cells, A549 cells
Figure 3. CEACAM1 expression differs in contact-inhibited and proliferating A549 cells. A) For quantification of CEACAM1 cell surface
expression in confluent and log phase cultured A549 cells, samples were analyzed by flow cytometry utilizing the QuiFiKit approach as described in
Materials and Methods. Briefly, cells were stained for CEACAM1 with mAb clone 283340. Fluorescence was quantitated using QuiFiKit calibration-
beads as described in Materials and Methods. The data shown are means 6 SD (*p#0.007) of three different experiments. B) Immunoblot analyses of
confluent and proliferating A549 cell lysates were done as described in Materials and Methods using monospecific mAbs directed against CEACAM1
(clone 283340), CEACAM5 (Col-1), and CEACAM6 (9A6), respectively and visualized by HRP-coupled secondary antibody and ECL detection. Beta-actin
served as a loading control. The blots shown are representative of three separate experiments. C) The fraction of CEACAM1 expressing A549 cells
increased over time as cells were kept in the confluent state. To analyze the CEACAM1 expression in A549 cells grown to confluence (day 0), plus 1
day, plus 3 days, plus 5 days and plus 7 days, cells were stained with mAb clone 283340 (thick line) and isotype matched control antibody (thin line)
followed by FITC-conjugated secondary antibody. Subsequently, samples were measured by flow cytometry. The data shown are representative of
three different experiments.
doi:10.1371/journal.pone.0008747.g003
Figure 4. Four CEACAM1 splice variants are expressed in
confluent A549 cells. RT of RNA isolated from confluent A549 cells
were applied to four different PCR reactions using primer pairs specific
four each of the four CEACAM1 isoforms. Products corresponding to
CEACAM1-4L (266 bp), CEACAM1-4S (245 bp), CEACAM1-3L (177 bp),
and CEACAM1-3S (145 bp), respectively, were amplified. The size of
oligonucleotide markers is shown on the left.
doi:10.1371/journal.pone.0008747.g004
Table 1. Characterization of the CEACAM1 isoform pattern as
determined by quantitative RT-PCR of the two A549
subpopulations.
A549-NT A549-T
Confluent/G0 Confluent/G0
CEACAM1-4L 104.600647.600 74.970633.000
CEACAM1-4S 23.49061.420 9.25065.570
CEACAM1-3L 13.30061.980 7.59062.930
CEACAM1-3S 58.87063.470 26.33067.430
[Copies/mg] [Copies/mg]
doi:10.1371/journal.pone.0008747.t001
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PLoS ONE | www.plosone.org 5 January 2010 | Volume 5 | Issue 1 | e8747Figure 5. CEACAM1-L but not CEACAM1-S secures cell contact-inhibition. A) Analyses of the cell surface expression of different CEACAMs in
the non-confluent log phase cultured parental A549 cells stably transfected with an empty vector (a), CEACAM1-4L (b), the mutant form of the
intracellular ITIM motif CEACAM1-4L-Y459F/Y486F (c) and CEACAM5 (d). Samples were analyzed by flow cytometry using mAbs that specifically bind
the different CEACAMs (thick line) or isotype matched control antibody (thin line) followed by FITC-conjugated secondary antibody. Data show one of
three different, representative stably transfected A549 clones. B) Representative phase contrast images demonstrating the morphology of A549 cells
stably transfected with empty vector (a), plasmids encoding for CEACAM1-4L (b), the ITIM mutant form CEACAM1-4L(Y459F/Y486F) (c), CEACAM5 (d)
and CEACAM1-4S (e). Bar, 50 mm. C) Percentage of viable cells determined by the flow cytometry based annexin V-FITC/PI approach as described in
Materials and Methods using cell spheroidals and aggregates harvested from the culture supernatant of wild type (wt) A549 cells and A549 cells
transfected with control vector, CEACAM1-4L (Y459F/Y486F) or A549-CEACAM5. Data are shown as the percentage of viable cells as the mean of
three independent experiments +/2 Standard deviation. D) Growth properties of control vector transfected and CEACAM1-4L transfected A549 cells
as determined by the MTS based method as described in Materials and Methods. A549- vector (white circles) and A549-CEACAM1 transfected cells
(black circles) were seeded into in 96-well cell culture plates at a density of 25,000 cells/well. Following standard cell culture for 1, 2, 3, 4 and 5 days,
respectively, the tetrazolium compound MTS was added and the samples were incubated at 37uC in a humidified, 5% CO2 atmosphere for 4 h.
Experiments were performed in triplicate and results presented are expressed as means of OD 490 nm 6 SD (*p#0.005). The data show one
representative result of three independent repeats of the experiment.
doi:10.1371/journal.pone.0008747.g005
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failed to grow as a homogenous monolayer. These cells barely
established cell-matrix and cell-cell-contacts and appeared mainly
as rounded cells. They grew as scattered, slightly attached cell-
aggregates without forming solid monolayers (Figure 5B, c).
Additionally, a number of A549-CEACAM1-4L (Y459F/Y486F)
cells grew in suspension (data not shown), supporting an essential
role of CEACAM1-4L in the mediation of contact inhibition of
cell proliferation.
Finally, morphological analyses of the A549-CEACAM5 cells
revealed that they grew as tight epithelial-like monolayers,
although in contrast to the CEACAM1-4L over-expressing cells,
A549-CEACAM5 cells tended to pile up on the monolayer,
implying continued cell proliferation (Figure 5B, d). However,
unlike un-transfected and control vector transfected cells, they did
not form spheroidal cell aggregates, but displayed a number of
single cells with a shriveled appearance on the top of the
monolayer (Figure 5B, d). Subsequent flow cytometric apoptosis
assays of the cells harvested from the different culture supernatants
revealed that the survival of detached A549-CEACAM5 cells was
significantly decreased compared with detached wild type A549,
A549-control vector and A549-CEACAM1-4L(Y459F/Y486F)
cells (Figure 5C).
Different CEACAMs Are Involved in the Modulation of
A549 Cell Proliferation
Next we investigated whether the expression of different
CEACAMs promotes cell expansion, by measuring cell prolifer-
ation rates. We detected no significant alterations in the
proliferation rates of parental A549 cells and A549 cells
transfected with a control vector (Figure 5D, open circles),
CEACAM1-4L (Figure 5D, filled circles), CEACAM1-
4L(Y459F/Y486F) and CEACAM5 (data not shown) during the
first two days after plating the cells at low cell number.
Interestingly, after becoming confluent on day 3, A549-CEA-
CAM1-4L cells stopped proliferating (Figure 5D, filled circles),
whereas A549-control vector (Figure 5D, open circles), A549-
CEACAM1-4L (Y459F/Y486F), and A549-CEACAM5 cells,
continued to proliferate (data not shown). As an additional marker
of cellular action we measured the acidification of the cell culture
supernatant. Normally, the pH value of the cell culture
supernatant of tightly confluent contact inhibited cells stays
neutral, but decreases in non-contact inhibited cultures due to
sustained metabolism. Therefore, we determined the pH values in
the 5 days cell culture supernatants of the different confluent A549
cell lines. We detected a significant drop from pH 7.4 to about
pH 6.6 in the supernatant of tightly confluent wild type A549,
A549-control vector, A549-CEACAM1-4L (Y459F/Y486F) and
A549-CEACAM5 cells, but not of confluent A549-CEACAM1-4L
cells (data not shown). Thus, our results indicate that CEACAM1-
4L negatively regulates proliferation of A549 cells by maintaining
contact inhibition via its ITIM domain.
CEACAM6 Induces A549 Cell Proliferation and Interferes
with CEACAM1-4L Mediated Contact Inhibition
In confluent A549-NT cells only CEACAM1 was expressed on
the cell surface. However, 10–15 per cent of the A549-T cells also
expressed CEACAM6 (Figure 2A). Therefore, we assumed that
the expression of CEACAM6 might be of importance for the
induction of proliferation by overcoming the CEACAM1-4L
mediated contact inhibition. To investigate this hypothesis,
confluent A549-T cells were divided by magnetic bead separation
into CEACAM6-negative and CEACAM6-positive subpopula-
tions. Subsequently, the expression levels of the proliferation
marker Ki-67 were evaluated by immunoblotting. As shown in
Figure 6A, only the CEACAM6-positive subpopulations of
confluent A549-T revealed a significant level of Ki-67 suggesting
involvement of CEACAM6 in the induction of cell proliferation.
To further investigate this observation, we determined the growth
phase of the cells by measuring the DNA content as an additional
marker of proliferation. Our results confirmed that CEACAM6
negative A549 cells were found only in the G0/G1 phase, whereas
CEACAM6 positive A549 cells showed active cell cycling with
high proportions of cells being in both the S-phase and the G2/M
phase (Figure 6B). To further substantiate our results, we
performed RNA interference experiments by stable transfection
of A549-T cells either with scrambled sh-control plasmids or with
shCEACAM6-plasmids. Flow cytometric (Figure 6C) and ELISA
analyses (data not shown) of A549-T cells transfected with the
different shCEACAM6-plasmids confirmed the complete absence
of CEACAM6 expression in the confluent growth stage, while
CEACAM1 was still expressed. Next, we investigated the
morphology of the monolayer in the confluent stage and found,
that A549-T-sh CEACAM6 monolayers had a cobblestone-like
morphology consisting of closely associated cells, comparable to
the morphology found in the A549-NT and A549-CEACAM1-4L
cells (Figure 6D). Moreover, in confluent CEACAM6 shRNA
plasmid transfected A549 cells neither spheroidal cell clusters nor
media acidification, indicating impairment of contact inhibition,
was observed.
Discussion
In the present study, we provide new insights into the
multiplicity and diversity of CEACAM1, CEACAM5 and
CEACAM6 expression and their functions in tumor development
and progression. We found, that CEACAM1 but not CEACAM5,
6, or 7 was expressed on the surface of A549 human alveolar lung
epithelial cells. However, this CEACAM1 expression was limited
to the post-confluent contact inhibited growth stage, whereas
proliferating cells did not show any CEACAM expression on the
cell surface. In addition to the expression of CEACAM1 in
contact-inhibited A549 cells, significant amounts of soluble
variants of CEACAM5 and CEACAM6 were released by
confluent A549 cells, thus exhibiting a likely source for increased
CEACAM5 and CEACAM6 serum levels, which are frequently
detected in cancer patients[31–33].
Further important insights from this study rely on the
characterization of two functionally distinct A549 subpopulations,
named A549-NT and A549-T. Cells of the A549-NT subpopu-
lation retains the characteristics of a more differentiated, contact-
inhibited cell type without tumorigenic effects in the nude mouse
system, whereas A549-T cells exhibit a relatively undifferentiated,
anchorage-independent cell growth. Accordingly, cells of this
subpopulation appear to be highly tumorigenic in nude mice[3].
Loss of contact inhibition and the gain of anchorage-independent
cell growth are hallmarks of undifferentiated cancer cells in vitro
6.
Thus, the A549 cell line is an excellent model system to investigate
normal and malignant cellular processes and tissue architecture,
which are known to be largely established and maintained by
members of the CEACAM family. In our study analyses of the two
A549 subpopulations reveals that CEACAM1-4L negatively
regulates proliferation by maintaining contact inhibition via its
ITIM-domain. These findings are in accordance with previous
reports describing CEACAM1 as a tumor-suppressor gene[34].
Interestingly, a fraction of tightly confluent A549-T cells also
expressed CEACAM6 on the cell surface. These CEACAM6
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PLoS ONE | www.plosone.org 7 January 2010 | Volume 5 | Issue 1 | e8747Figure 6. CEACAM6 acts as an inducer of cellular proliferation in confluent A549. A) The expression of the proliferation marker Ki67 is
limited to A549-T cells that also expressed CEACAM6 on their cell surface. Confluent CEACAM6-negative and CEACAM6-positive A549-T cells were
separated by mAb 9A6 loaded magnetic protein G microbeads and mMAS magnetic sorting columns (Miltenyi Biotec) as described in Materials and
Methods. Immunoblot analysis of confluent CEACAM6-negative and CEACAM6-positive A549-T cell lysates was performed applying a Ki67 specific
antibody followed by HRP-coupled secondary antibody and ECL detection. Beta-actin served as a loading control. The data shown are representative
of three separate experiments. B) Cell cycle analysis of CEACAM6 negative and CEACAM6 positive A549-T cells. CEACAM6-negative and CEACAM6-
positive A549 cells were fixed in 80% ethanol and stained with propidium iodide, and analyzed by flow cytometry as described in ‘‘Materials and
Methods.’’ The DNA content in the different cell fractions is given in arbitrary units on the X-axis. Cells in the G2-M phase (second peak) contained
twice as much DNA as cells in the G0-G1 phase (first peak). Cells between the peaks represent cells in the S-phase. The relative proportions of cells in
the various phases are shown above the DNA profiles. Filled curve, CEACAM6 negative A549 cells; thick curve, CEACAM6 positive A549 cells. C)
Confluent control sh-plasmid transfected A549-T (A549-shControl) and shCEACAM6 transfected A549-T cells (A549-shCC6) were stained for CEACAM1
with mAb clone 283340 and for CEACAM6 with mAb 9A6 (thick lines). The background fluorescence was determined by incubating the cells with
control IgG antibody (thin lines). Samples were analyzed by flow cytometry. Compared to A549-shControl cells, A549-shCC6 cells completely lacked
CEACAM6 expression, but continued to express CEACAM1. D) Phase contrast images of (a) control sh-plasmid transfected A549-T and (b) shCEACAM6
transfected A549-T cells. Confluent control sh-plasmid transfected A549-T piled up and formed unanchored spheroidal cell aggregates on top of the
monolayer revealing insufficient contact inhibition. (b) In contrast, A549-shCC6 cells formed well spread monolayers without detection of
unanchored, spheroidal cell growth indicative tight contact inhibition. Bar, 50 mm.
doi:10.1371/journal.pone.0008747.g006
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DNA-based cell cycle profile characteristic for dividing cells, two
well-known markers of cellular proliferation. Our data indicate
that CEACAM6 expression on the surface of A549 cells abolishes
the cell-cell contact-triggered inhibitory signal mediated by
CEACAM1. Consequently, we conclude that CEACAM6 expres-
sion on the cell surface acts as a potent inducer of cellular
proliferation. Moreover, these observations are of central impor-
tance for explaining the differences in growth behavior and
tumorigenicity of A549-NT and A549-T cells. These findings
demonstrate that the interplay between different CEACAMs is
crucial for the regulation of cell proliferation and growth arrest.
Furthermore, over-expression of CEACAM1-4L strengthened
contact inhibition and the formation of tightly confluent
monolayers which were dependent on the presence of an intact
ITIM domain in the cytoplasmic part of CEACAM1-4L. Our data
are in accordance with several reports indicating tumor suppres-
sive functions when the CEACAM1-4L gene was over-expressed
in prostate, bladder, colon and breast cancer cells. In these studies,
over-expression of CEACAM1-4L lead to significantly lower
growth rates and less tumorigenicity in both in vitro and in vivo
models when compared with un-transfected tumor cells [32–36].
In addition, we found that A549 cells over-expressing the
cytoplasmic S-isoform of CEACAM1 on their cell surface
completely lost the ability to grow as an epithelial monolayer.
These data correspond to a report of Wang et al. [36]. In this
study the authors analyzed tumor tissue and corresponding normal
lung tissue from patients with non-small cell lung cancer (NSCLC)
and found reduced expression levels of the L-form of CEACAM1
as well as increased levels of the S-form of CEACAM1 in most of
the lung cancer tissues
36. Changes in the isoform ratios of
CEACAM1 favoring the S form has already been demonstrated to
increase proliferation in cancer cells [37,38]. However, in our
investigation we did not find a significant difference in the L/S
ratio expressed by the two A549 subpopulations that would
account for the differences in the observed growth pattern.
As mentioned above, in contrast to the A549-NT cells, in
addition to CEACAM1, about 15 percent of the A549-T cells also
expressed CEACAM6 on their cell surface, and the alterations in
contact inhibited growth pattern could be reversed in A549-T cells
by shRNA mediated knock down of CEACAM6 expression.
CEACAM6 expression has already been inversely correlated with
cellular differentiation and has been identified as a marker for
decreased survival in patients with CEACAM6 expressing
cancers.[35,37,38] In a series of experiments, Duxbury and
associates have demonstrated that CEACAM6 over-expression
in pancreatic cancer is a determinant of cell proliferation and cell
invasiveness[39]. On the other hand, targeting CEACAM6 results
in decreased tumor growth, and inhibits metastases in a mouse
xenograft model[40]. Our results are in accordance with these
findings, but in addition we show for the first time that
CEACAM6 acts as an inducer of proliferation in A549 cells,
putatively by interfering directly or indirectly with the contact-
inhibiting signal triggered by CEACAM1-4L. These data also
support previous data implying that CEACAM6 over-expression
inhibits the tissue architecture surveillance mechanism known as
anoikis[41]. In principle A549 cells were able to express GPI
anchored CEACAMs as demonstrated by the generation of A549-
CEACAM5 cell lines (Figure 5A). However, our finding that the
survival of detached A549-CEACAM5 cells was significantly
decreased was in contrast to the results published by Camacho-
Leal and Stanners, who demonstrated that the GPI anchor of
CEACAM5 mediates anoikis inhibition[42]. This different result
may be based on the fact that A549 cells represent a human cell
system endogenously expressing CEACAMs whereas Stanners
group utilized L6 rat myoblasts, which normally do not express
CEACAM5. In addition, in rat no GPI-linked CEACAMs were
described so far.
Our observations seem to be in contrast to the report of Laack
et al., who identified CEACAM1 expression as a prognostic
marker for poor outcome in patients with adenocarcinomas of the
lung[43]. However, Sienel et al. suggested that the unfavorable
prognostic influence of CEACAM1 might be derived from its
angiogenic influence leading to an increased angiogenic activity
and micro vessel density (MVD) in non-small-cell lung cancer. It is
tempting to speculate that the expression of other CEACAMs in
NSCLC cells could overcome the CEACAM1-mediated contact
inhibition in these cells.
Taken together, several members of the CEACAM family play
important roles in tumorigenesis and the development of
metastatic disease[10,14]. In addition, each CEACAM and each
CEACAM splice variant can exhibit distinct functions, and
interactions between different CEACAMs seem to play a central
role in the fine-tuning of several cellular functions[12,38].
Nevertheless, in most studies of the role of CEACAM expression
in cancer cells, the expression and function of only one CEACAM
was investigated[11,12,22,34–36,40,44–52]. The results of our
study show that changes in the expression patterns of different
CEACAMs can alter their diverse functions on cell-cell interac-
tions leading to changes in differentiation and survival, as well as
tumorigenicity. Thus, future studies should focus on the expression
patterns and the functional interplay of all CEACAMs and
CEACAM isoforms expressed on the investigated tissues.
Materials and Methods
Antibodies and Reagents
The media and media supplements were purchased from
Gibco-Life Technology (Eggenstein, Germany) and the chemicals
were obtained from Sigma (Taufkirchen, Germany), unless stated
differently.
The hybridoma secreting the mouse mAb 18/20 (specific for
human CEACAM1/3/5) was recently described[20]. The mAb
Col-1 was purchased from Invitrogen (Carlsbad, CA) and the anti-
human CEACAM1 mAb clone 283340 from R&D systems
(Minneapolis, MN). Anti-human CEA/CEACAM5 mAb clone
CI-P83-1 was obtained from Dianova (Hamburg, Germany). The
mAbs 9A6 (specific for CEACAM6) and BAC2 (specific for
CEACAM7) were provided by Genovac (Freiburg, Germany).
The CEACAM8-specific mAb 80H3 was obtained from Coulter
International (Miami, FL). The rabbit anti-CEA (binding
CEACAM1/3/4/5/6/7/8) and the polyclonal antibody for Ki-
67 were obtained from Dako (Copenhagen, Danmark). The anti-
beta-actin-peroxidase antibody (clone AC-15) was purchased from
Sigma. FITC- and HRP-coupled secondary goat anti-mouse IgG
F(ab)2 fragments were obtained from Jackson ImmunoResearch
(West Grove, PA).
Cells
A549 epithelial cells (type II alveolar lung epithelium cells;
ATCC CCL85) were cultured in DMEM (GIBCO) supplemented
with 10% (v/v) heat inactivated fetal calf serum (FCS) and 4 mM
L-glutamine at 37uC in a humidified atmosphere with 5% CO2.
A549 cells analyzed as growing in log phase were in the mid-
logarithmic phase of growth, while confluent cells were cultivated
until tight cell-cell contacts were developed. The cell spheroids
were collected from the supernatant of tight confluent growing
cells. In all cases, cell viability was over 90% as measured by
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different growth stages were monitored by standard phase contrast
microscopy utilizing the Leica DMIL-system (Leica Microsystems,
Wetzlar, Germany) and the ProgRes Capture Pro2.5 analyses
software (Jenoptik, Jena, Germany).
Cell Separation
The separation of A549 cells into subpopulations was performed
as described by Croce et al. Briefly parental exponentially growing
cells were harvested by the standard trypsinization procedure and
separated by Percoll density gradients (GE Healthcare). Thus, cells
were re-suspended in 1.5 ml PBS and carefully layered on top of
the Percoll gradient consisting of 1.5 ml of each stock solution of
density 1.035, 1.040, 1.050, 1.060, 1.065, 1.070 and 1.080 g/ml
prepared according to the manufacturer’s protocol. The gradients
were centrifuged at room temperature at 800 g for 40 min in a
swinging-bucker rotor without using the brake. Fractions of 0.5 ml
were collected from the top, and the samples were washed twice
with DMEM. The cell number in each fraction was determined by
counting in a Neubauer chamber and cell viability was determined
by trypan blue exclusion. Cells were then plated and cultured as
described above until further use.
For some experiments, CEACAM6-positive and CEACAM6-
negative parental A549 cells were separated using magnetic
protein G microbeads (Miltenyi Biotec, Bergisch Gladbach,
Germany) coupled with the CEACAM6-specific mAb 9A6. Thus,
cells were incubated with protein G-mAb 9A6 microbeads for 1 h
in medium on ice. Next, cells were applied to mMAS magnetic
sorting columns (Miltenyi Biotec) and the further separation steps
were performed according to the manufacturer’s protocol. The
quality of separation was monitored by flow cytometry.
Cell Proliferation Assay
For colorimetric determination of cell proliferation, the A549
cells and A549-CEACAM1-4L transfectants were plated in a 96-
well cell culture plate at a density of 25,000 cells/well in triplicate.
Following standard cell culture the tetrazolium compound MTS of
the CellTiter96 Aqueous One assay (Promega Corp., Madison,
WI) was added to each well. Then cells were incubated at 37uCi n
a humidified 5% CO2 atmosphere for 4 h. The absorbance of
soluble formazan produced by cellular reduction of the MTS was
measured at 490 nm using a microplate reader (Tecan, Craisl-
heim, Germany). The quantity of formazan product, as measured
by the amount of 490 nm absorbance, is directly proportional to
the number of living cells in culture. Experiments were performed
in triplicate and the results presented were expressed as the OD at
490 nm.
Measurement of the Acidification in the Cell Supernatant
Cell culture acidification was determined utilizing cell-free
supernatant fluid for estimating the pH value by the color change
of the tracer in the media and by pH-indicator strips pH 5.2 – 7.2
(Merck, Darmstadt, Germany). Media was considered as acidified
if the pH decreased from pH 7.3 to below pH 6.5.
Transfection
A549 cell lines, permanently expressing CEACAM1-4L,
CEACAM1-4S, CEACAM5 and CEACAM6, respectively, were
generated. The pRC-CMV-based NEO-resistant expression
plasmids encoding either CEACAM1-4L, CEACAM1-4S or a
variant of CEACAM1-4L with mutations in the cytoplasmic ITIM
(exchange of Y459 to F459 and Y486 to F486), (kindly provided by
Prof. W. Zimmermann, University Clinic – Grosshadern, Ludwig-
Maximilians-University Munich, Germany), CEACAM5-pRc/
CMV (kindly provided by Dr. Grunert, Institute of Immunology,
Freiburg, Germany) or CEACAM6-pdKCR-neo (kindly provided
by Dr. M. Kuroki, Department of Biochemistry, Fukuoka
University, Fukuoka, Japan) were transfected into parental A549
using lipofectamine 2000 according to the manufacturer’s protocol
(Invitrogen). Stable transfected cells were selected in culture
medium containing 1 mg/ml of Geniticinsulfat (G418, Biochrom,
Berlin, Germany). The surface expression of CEACAMs in
individual clones growing in log phase was determined by flow
cytometry. Three independent clones of each transfection were
analyzed to confirm consistent behavior and receptor expression.
Small/Short Hairpin RNA (shRNA) Interference in A549
Cells
Gene silencing of CEACAM6 was performed with pre-designed
SureSilencing
TM CEACAM6-shRNA plasmids (Super Array-
Bioscience Corporation) containing four pooled shRNA sequences
to ensure an effective depletion of CEACAM6 in A549 cells. The
shRNA-CEACAM6 sequences were as follows:
Clone ID 1: 59-ACGATGCAGGATCCTATGAAT-39;
Clone ID 2: 59-AACGATGCAGGATCCTATGAA-39;
Clone ID 3: 59-GAACGATGCAGGATCCTATGA-39;
Clone ID 4: 59-GTAGAGTGGTGCTGCTTTAAT-39;
The scrambled 59-GGAATCTCATTCGATGCATAC-39 se-
quence (sh-CON) served as a control. The stable A549 shRNA
transfection was carried out with Lipofectamine 2000 (Invitrogen)
followed by selection for 2–3 weeks in 1 mg/mL G418-containing
medium. Two control clones (sh-CON-A549) and three clones of
CEACAM-silenced A549 cells were chosen and further charac-
terized by flow cytometry and Western blot.
Immunoblot Analysis
Cells were lysed in RIPA based lysis buffer [50 mM Tris-HCl,
pH 7.5, 150 mM NaCl, 1% Triton X-100, 0.5% sodium
deoxycholate) supplemented with protease inhibitor cocktail set
III (Calbiochem) and PhosSTOP phosphatase inhibitor cocktail
(Roche) on ice for 30 min. Lysates were centrifuged at 10,000 g at
4uC for 15 min and approximately 50 mg of total protein was
subjected to SDS-PAGE, blotted to membrane (Schleicher &
Schuell, Dassel, Germany) and reacted with anti-CEACAM1,
anti-CEACAM5, anti-CEACAM6 and anti Ki67. Anti-beta-actin
antibody was used as Western blot loading control.
Relative and Quantitative Flow Cytometry
A549 cells (5610
5) were stained with mAbs (20 mg/ml) anti-
CEACAM1 (clone 283340), anti-CEACAM5 (Col-1) anti-CEA-
CAM6 (9A6), anti-CEACAM7 (BAC2) and anti-CEACAM8
(80H3) diluted in 3% FCS/PBS for 1 h on ice, washed with ice-
cold PBS, and incubated with FITC conjugated anti-mouse
F(ab’)2. Background fluorescence was determined using isotype-
matched Ig. For DNA quantification, the cells were fixed in ice
cold 80% ethanol and then were incubated for 15 min at 37uCi n
PBS containing 100 mg/ml DNase-free RNase (Sigma), and
10 mg/ml propidium iodide. The stained cell samples were
examined in a FACScalibur flow cytometer (BD Biosciences,
San Diego, CA) and the data were analyzed utilizing the
CellQuest software. Where applicable, dead cells, identified by
PI staining, were excluded from the determination.
The absolute quantitative expression pattern of the different
CEACAM-proteins was determined using QuiFiKitH (Dako,
Glostrup, Denmark) according to the manufacturer’s protocol.
Hence, the calibration-bead suspension coated with known
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undergoing secondary staining procedure with FITC conjugated
anti-mouse F(ab’)2. Utilizing the median values of the calibration
beads, a calibration curve was constructed and the absolute
numbers of CEACAM-molecules per cell were calculated.
Sandwich-ELISA
A549 cell culture supernatants were collected from cells grown
to confluence plus 6 days (A549confluent). After centrifugation at
10,0006g, the samples were stored at 280uC until further use.
The evaluation of CEACAM1, CEACAM5 and CEACAM6 was
performed by sandwich-ELISA. In brief, 96-well flat bottom
immunoassay MaxiSorpELISA plates (Nunc Maxisorp, Invitro-
gen) were coated overnight at 4uC with 1 mg/well rabbit anti-
human CEA antibody (Dako). After three washes with PBS, plates
were blocked with 350 ml/well of PBS/3% BSA for 1 h at room
temperature. Thereafter, 100 ml/well of two-fold dilutions of
supernatants in PBS/1% BSA were added. As positive antigen
controls, cell lysates of Hela, Hela-CEACAM1-4L, Hela-CEA-
CAM5, Hela-CEACAM6, Hela-CEACAM7 and Hela-CEA-
CAM8 cells were added. Plates were then incubated at 4uC
overnight. After washing, 1 mg/100 ml/well of mAb anti-CEA-
CAM1 (clone 283340), anti-CEACAM5 (Col-1, CI-P83-1), anti-
CEACAM6 (9A6), anti-CEACAM7 (BAC2) or anti-CEACAM8
(80H3) diluted in 1% FCS/PBS was added and incubated for 4 h
at room temperature. After washing, HRP-conjugated anti-mouse
F(ab’)2 was added and incubated for 2 h at room temperature.
Finally, the plates were washed 4 times, developed using TMB
(Sigma) according to the manufacturer’s protocol, and the
absorbance was detected at 450 nm in a Sunrise-ELISA reader
(Tecan, Crailsheim, Germany). All measurements were deter-
mined in triplicates.
Quantitative RT- PCR
Specific primers (table 2) were designed to estimate the amount
of four different CEACAM1 isoforms: CEACAM1-4L was
detected with the CEACAM1-4 sense primer and CEACAM1-L
antisense primer, CEACAM1-4S cDNA was amplified with
CEACAM1-4 sense primer and CEACAM1-S antisense primer.
The CEACAM1-3L cDNA was detected with the CEACAM1-3
sense primer and CEACAM1-L antisense primer and CEA-
CAM1-3S cDNA was ascertained with CEACAM1-3 sense primer
and CEACAM1-S antisense primer. The primers were purchased
from Eurofins MWG Operon (Ebersberg, Germany). An internal
standard for each CEACAM1 isoform was generated utilizing an
endpoint PCR using 1 ml cDNA, 0.2 U Taq polymerase (Gene-
craft, Luedinghausen, Germany), 2 mmol/l dNTP, 3 ml 10x buffer,
0.5 mmol/l of the respective sense and antisense primers (table 2)
in a final volume of 30 ml under standard conditions (95uC for
3 min followed by 34 cycles at 95uC for 30 sec, 60uC for 45 sec
and 72uC for 30 sec and an extension at 72uC for 8 min).
Afterwards the PCR products were purified with PCR purification
kit (Qiagen, Hilden, Germany) and cloned in the pDrive cloning
vector with the PCR cloning kit (Qiagen, Hilden, Germany)
according to the manufacturers protocol. Colonies were picked
and the presence of the PCR product in the isolated DNA was
verified by sequencing. The appropriate plasmid containing the
PCR product was used as a specific qPCR standard.
The total RNA of A549 cells was isolated using the Qiagen
RNeasy Kit. Afterwards 1 mg of each sample was reverse
transcribed with the QuantiTect Reverse Transcription Kit
(Qiagen) in a final volume of 20 ml. For each gene a qPCR was
performed by using 1 ml of cDNA, the adequate standard-DNA
(10
3–10
8 molecules) and blanks with the SYBRgreen master mix
(Bio-Rad) and suitable primers (see above) in a final volume of
25 ml according to the manufacturers protocol with the IQ5 cycler
(Bio-Rad). The qPCR products were visualized using 3% agarose
gel/Tris-acetate-EDTA separation and ethidium bromide stain-
ing, and then the total amounts of molecules/well were
determined using the IQ5 software (Bio-Rad) the GenEx
professional software (Multid, Go ¨teborg, Sweden).
Statistical Analysis
Where applicable, data are presented as the mean 6 SD.
Statistical significance was determined using the Student’s t-test.
Differences were considered to be statistically significant at a P
value of ,0.05.
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